Optimizing Management Approaches in Patients with Moderate-to-Severe Atopic Dermatitis

Allergy/ Immunology
The Learning Pathway in Atopic Dermatitis: Optimizing Management Approaches in Patients with Moderate-to-Severe Disease
0.75 AMA PRA Category 1 Credit(s)
Launch Date:
March 27, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Dermatology clinicians who manage patients with moderate-to-severe atopic dermatitis (AD)

Relevant Terms:

Atopic Dermatitis (AD)

Mark Lebwohl, MD

Mark Lebwohl, MD (Chair)
Kimberly and Eric J. Waldman Professor of Dermatology
Icahn School of Medicine at Mount Sinai
Chairman, Kimberly and Eric J. Waldman Department of Dermatology
Mount Sinai Health System
New York, NY

Mark Lebwohl, MD, is the professor and chairman of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, NY. He received his degree in medicine from Harvard Medical School in Boston, MA and completed his internship and residency in internal medicine, as well as his residency in dermatology, at Mount Sinai Hospital in New York. 
Dr Lebwohl's key interests in clinical research include skin cancer and inflammatory skin diseases, including psoriasis, atopic dermatitis, vitiligo, and alopecia areata. Dr Lebwohl identified one of the first topical therapies approved for skin cancer and precancerous lesions. In addition, many of the systemic and topical therapies for psoriasis and atopic dermatitis were investigated or developed in the Department of Dermatology at Mount Sinai. 

Dr Lebwohl has authored or coauthored nearly 500 original peer-reviewed original reports, 400 invited articles and other publications, and approximately 250 Abstracts. Notably, he is the author of the first atlas, Atlas of the Skin of Systemic Disease, which is dedicated to cutaneous manifestations of systemic disease and coeditor of Treatment of Skin Disease, a leading textbook in dermatology that has been translated into several languages, won several medical book awards, and is in its 5th edition.

Dr Lebwohl is the founding editor and current co-editor-in-chief of the Journal of Psoriasis and Psoriatic Arthritis and Skin, the Journal of Cutaneous Medicine. He has served on many editorial boards, including the Journal of the European Academy of Dermato-Venereology, the Latin American Journal of Psoriasis and Psoriatic Arthritis, the Journal of Skin Cancer, and the Journal of the American Academy of Dermatology. Currently, he is the editor of the dermatology section of Scientific American Medicine. In addition, as a renowned expert in dermatology, Dr Lebwohl is frequently an invited visiting professor and speaker at universities, medical centers, conferences, and symposia worldwide. 
Active in a number of professional organizations, Dr Lebwohl is an honorary member of the French Society of Dermatology and the Canadian Dermatology Association. He is past president of the American Academy of Dermatology and chairman emeritus of the Medical Board of the National Psoriasis Foundation. Dr Lebwohl serves on the International Psoriasis Council.  

Throughout his distinguished career, Dr Lebwohl has been the recipient of many awards, such as the Presidential Citation from the American Academy of Dermatology for his service on psoriasis and for his work with the Psoriasis Foundation. Furthermore, he has received Lifetime Achievement Awards from the National Psoriasis Foundation and American Skin Association, and has been recognized as a Leader of Distinction by the Journal of Drugs in Dermatology for his work in psoriasis. In addition, Dr Lebwohl was the honorary chairman of the 1st World Psoriasis and Psoriatic Arthritis Conference held in Stockholm, Sweden in 2006 by the International Federation of Psoriasis Associations and its patron, His Majesty King Carl Gustav of Sweden.

Emma Guttman, MD, PhD

Emma Guttman, MD, PhD 
Professor of Dermatology, Sol and Clara Kest 
Icahn School of Medicine at Mount Sinai 
New York, NY

Emma Guttman, MD, PhD, the Sol and Clara Kest professor of dermatology, is vice chair for research at the Department of Dermatology, director of the Center for Excellence in Eczema, and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center, New York. She earned her medical degree from Sackler in Tel-Aviv, and a doctorate degree from Bar-Ilan, Israel. After her Israeli board certification in dermatology at the Rambam Medical Center at the Technion, Dr Guttman moved to the United States to pursue a postdoctoral fellowship at Laboratory for Investigative Dermatology at The Rockefeller University and a second dermatology residency at Weill-Cornell, NY. 

Dr Guttman's major focus is atopic dermatitis (AD) or eczema. She made paradigm-shifting discoveries on the immunologic basis of AD/eczema in humans, enriching the understanding of its pathophysiology and opening the door to new therapeutics. Dr Guttman has developed comprehensive molecular maps of AD, defining skin differentiation and immune-circuits characterizing this disease. She has established the reversibility of the AD phenotype and defined a series of biomarkers that are now accelerating testing of novel pathway-specific drugs for AD. Her research on atopic dermatitis/eczema has contributed directly to the recently developed treatments for this disease, earning her a unique place in dermatology and immunology worldwide. She is now testing (both clinically and mechanistically) multiple targeted therapeutics for atopic dermatitis that target Th2, Th22, and Th17/IL-23 axis. She has recently also extended her research interest to alopecia areata in which her findings are also translated to possible novel therapeutic targets. 

Dr Guttman has co-founded the international eczema council/IEC, for which she functions as president-elect. She was elected to the American Society for Clinical Investigation/ASCI, the American Dermatological Society/ADA, and received the Young Investigator Award from the American Academy of Dermatology, as well as several other awards. She has recently been elected to serve on the board of the American Skin Association. Dr Guttman is considered one of the world's leading experts in inflammatory skin diseases and authored more than 120 articles. She has also been featured as keynote speaker in many international and national meetings. Her achievements have been highlighted by the media including the New York Times, CBS News, Daily News, Reuters, Wall Street Journal, NY1, and others.

David M. Pariser, MD, FACP, FAAD

David M. Pariser, MD, FACP, FAAD
Professor of Dermatology
Eastern Virginia Medical School
Virginia Clinical Research
Pariser Dermatology Specialists
Norfolk, VA

David M. Pariser, MD, FACP, FAAD, is a professor in the Department of Dermatology at Eastern Virginia Medical School in Norfolk, VA. He is also the senior physician at Pariser Dermatology Specialists, Ltd., a private group practice of 13 dermatologists, 6 PAs, and 2 nurse practitioners, with multiple locations in Southeastern Virginia. Dr Pariser is the president and principal investigator for Virginia Clinical Research, Inc. and a former president of the American Academy of Dermatology (AAD) and the American Dermatological Association (ADA).

Dr Pariser obtained his undergraduate degree from the University of Pennsylvania, his medical degree from the Medical College of Virginia, and trained as a dermatology resident at the University of Miami. Dr Pariser is board certified in both dermatology and dermatopathology. He holds fellowships from the AAD, the American Society of Dermatopathology, and the American College of Physicians.

An active clinician and teacher, Dr Pariser has participated as a principal investigator in over 470 clinical trials. He has been a guest speaker at over 600 CME events all over the world, and is currently on the board of directors of the International League of Dermatologic Societies, the body that sponsors the World Congress of Dermatology.

Dr Pariser's primary clinical and research interests include atopic dermatitis, psoriasis, hyperhidrosis, acne, and photodynamic therapy. He has served on the medical advisory board of the National Psoriasis Foundation and is the immediate past president, and is currently the secretary and a board member of the International Hyperhidrosis Society. Very active in the affairs of the AAD, Dr Pariser was president and a board member of the Academy for 14 years. Currently, he is the chair of the AAD's Council on Community, Corporate, and Philanthropic Relations, which is the interface between the AAD and industry. He is a long-time advocate for the dermatology team care approach and for education, training, and proper supervision of PAs and nurse practitioners.

Dr Pariser is the author of 3 textbooks, multiple textbook chapters, nearly 50 invited papers, over 100 scientific poster presentations, and over 170 original works in peer-reviewed journals, with additional co-authorship of 22 AAD publications on guidelines of care. He is, or has been, on the editorial board of the Journal of the American Academy of Dermatology and Managed Care magazine, and is a reviewer for both of these publications and Pediatric Dermatology, the American Journal of Managed Care, the Journal of the European Academy of Dermatology and Venereology, and the Archives of Dermatology, now JAMA Dermatology.

Awards and honors presented to Dr Pariser include the Gold Triangle Award from the AAD for advocacy issues surrounding isotretinoin, 9 presidential citations from the AAD, honorary membership in the AAD, and Clinical Educator of the Year award from both the fall and winter Clinical Dermatology Conferences.

Dr Pariser is the 2017 awardee of the Gold Medal of the AAD, its highest award. The Gold Medal is presented on a highly selective basis in recognition of outstanding and exceptional service to the specialty of dermatology in science, teaching, and the practice of cutaneous medicine, surgery, as well as those who have made an outstanding and exceptional contribution to the administrative aspects of this specialty; nationally or internationally.
1. Apply current principles of pathophysiology of atopic dermatitis and the concept of atopic march to therapeutic approaches to disease management
2. Develop treatment plans for patients with atopic dermatitis that reflect evidence-based guidelines, use of new therapeutic options, and strategies to optimize short-term control and long-term management of the disease
3. Address quality-of-life issues and psychosocial comorbidities in managing patients with atopic dermatitis
4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Mark Lebwohl, MD, is an employee of Mount Sinai which receives research funds from: Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, Medimmune/Astra Zeneca, Novartis, Pfizer, Valeant, and ViDac; Allergan, Aqua Leo-pharma, and Promius (Consultant)
  • Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Eli Lilly, Escalier,  Galderma, Glenmark, Kiowa Kirin, Kymab, LEO Pharmaceuticals, Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Theravance, and Vitae (Consultant)
  • David M. Pariser, MD, FACP, FAAD, has affiliations with Bickel Biotechnology, Biofrontera AG, Celegene, Dermira, DUSA Pharmaceuticals, LEO Pharmaceuticals, Novartis, Promius, Regeneron, Sanofi, TheraVida, and Valeant (Consultant); Pfizer (Advisory Board); Abbott Laboratories, Amgen, Asana Biosciences, Bickel Biotechnology, Celgene, Dermavant Sciences, Eli Lilly, LEO Pharmaceuticals, Merck, Novartis, Novo Nordisk, Ortho Dermatologics, Peplin, Photocure, Promius, Regeneron, Stiefel, and Valeant (Contracted Research).  
RMEI Medical Education, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Misha Mutizwa, MD, has affiliations with Celgene (Consulting Fees).
  • Sharon Powell, has no affiliations with commercial interests to disclose.       
Postgraduate Institute for Medicine
The following PIM planners and managers: Judi Smelker-Mitchek, MBA, MSN, RN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 0.75 hour
Medium: Internet
There is no fee for this educational activity.
This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
By reviewing the course content and successfully completing the post-test and evaluation, physicians/DOs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.